Menu
  • The inaugural holding of the US E-Cigarette Summit will take place in Washington DC, on Monday May 8, 2017
  • Registration for the US E-Cigarette Summit 2017 is now open

E-Cigarette Summit USA 2017

Download a printable PDF of the agenda

08:15 - 08:20

Welcome from the Chair

  • Prof Thomas J. Glynn, PhD Consulting Professor - Stanford Prevention Research Centre, Stanford University School of Medicine


Context, Evidence, Data & Research


08:20 - 09:00

The Evidence on E-cigarettes: Evaluating What We Have and Identifying What We Need

The debate between e-cigarette enthusiasts and skeptics has evolved into a vitriolic stand-off in which basic philosophies and emotions play at least as important a role as sound analysis of empirical evidence. This presentation will examine the evidence, suggesting how a rational assessment of what we know today should frame communications and policy going forward. A core issue, also addressed in this presentation, is identification of remaining evidence needs. Not all unknowns are equally important. An analytical framework can help determine those that are most pressing.

  • Prof Kenneth E. Warner Avedis Donabedian Distinguished University Professor of Public Health - University of Michigan
09:00 - 09:15

Potential Harms of E-Cigarette Use in Youth

This session will consider several potential harms of e-cigarette use among adolescents and young adults including whether e-cigarette use increases the risk of cigarette smoking in these populations.

09:15 - 09:30

Global Trends in E-Cigarette Use -Understanding the data from beyond the USA

E-cigarettes are still relatively new devices and the extent of their use varies around the world. Rapid uptake has been identified in a number of developed countries, most notably in the UK and the USA where the majority of smokers have tried vaping, some have progressed to regular use, and some have stopped smoking using e-cigarettes. Rates of regular use in never smoking adults and youth remain very low, indicating that at the current time these devices are primarily used by smokers and ex-smokers. However, even within developed countries uptake has varied, often as a result of regulation with many countries restricting or prohibiting vaping. Recent research suggests these regulatory differences may have a role to play in the extent to which e-cigarettes can contribute to tobacco harm reduction. In the developing world, uptake of e-cigarettes by smokers remains low particularly in jurisdictions where tobacco is cheap and widely available and e-cigarettes are more expensive or more heavily regulated, although evidence on use in low and middle income countries is very limited. This presentation will aim to provide an overview of global trends using existing data, and highlight gaps in research and surveillance that could be addressed in future.

  • Professor Linda Bauld Professor of Health Policy - University of Stirling, UK Centre for Tobacco and Alcohol Studies (UKTAS) and Cancer Research UK
09:30 - 09:45

Improving E-Cigarette Research through Measurement and Design

Dr. Villanti will highlight lessons on conducting, interpreting, and improving e-cigarette research gleaned from conducting an ongoing systematic review of published health research on e-cigarettes.

  • Andrea Villanti, PhD, MPH Director of Regulatory Science and Policy - Schroeder Institute for Tobacco Research and Policy Studies at Truth Initiative and Associate Professor, Dept Psychiatry at University of Vermont
09:45 - 10:00

Who are Using E-Cigarettes and Why? Patterns and context of use.

Understanding the patterns and context of e-cigarette use is vital when assessing and measuring evidence.

10:00 - 10:30

Open floor Q&A : Understanding patterns of use of all tobacco and nicotine products:

  • What are common traits and behaviors across US and UK use patterns?
  • What is different between the US and UK regarding behavioral epidemiology?
  • Looking forward, what trends and patterns do we need to attend in particular?

  • Brian Carter PhD Volunteer - Director of Scientific Communications - CASAA
  • Prof Kenneth E. Warner Avedis Donabedian Distinguished University Professor of Public Health - University of Michigan
  • Professor Linda Bauld Professor of Health Policy - University of Stirling, UK Centre for Tobacco and Alcohol Studies (UKTAS) and Cancer Research UK
  • Andrea Villanti, PhD, MPH Director of Regulatory Science and Policy - Schroeder Institute for Tobacco Research and Policy Studies at Truth Initiative and Associate Professor, Dept Psychiatry at University of Vermont
  • Dr Robin Mermelstein Professor of Psychology and IHRP Director - University of Illinois, Chicago
  • Asst. Prof Samir Soneji Assistant Professor - The Dartmouth Institute for Health Policy and Clinical Practice
10:30 - 10:50

Morning Refreshment Break

 


Safety and Health Effects


10:50 - 11:05

Patient-Provider Communications on E-Cigarettes: Perceptions of safety & harm

What do patients want to know about e-cigarettes and how are clinicians responding? With e-cigarettes prevalent in the marketplace, patients are turning to health care providers for guidance. Patients’ questions center on concerns about specific side effects and harms, general safety, use as smoking quit aids, harm reduction benefits relative to combusted tobacco, use with pre-existing medical conditions, and nicotine-free options. With limited research evidence available, providers are responding the best that they can. This presentation will highlight key learnings from an analysis of online patient-provider communications on e-cigarettes and will point to resources available for health care providers to learn more.

11:05 - 11:20

Nicotine in Society by Mode of Delivery – Framing relative appeal, addiction and toxicity

Tobacco- and nicotine-containing products have evolved considerably in terms of their modes of delivery and corresponding harm potential. When nicotine is delivered in combustible tobacco products (e.g., cigarettes, cigars), addiction and persistent use results in devastating consequences. Less clear are nicotine’s effects when delivered in non-combustible tobacco products and, most recently, in forms that are increasingly separated from toxic tobacco and combustion by-products. This session will review the evidence regarding nicotine’s risk in terms of cardiovascular diseases and cancers as well as risks for adolescent brain development and addiction, and discuss challenges to one-size-fits-all tobacco control approaches that do not take into account risk differences and nicotine delivery profiles among tobacco and nicotine-containing products.

  • Dr. Raymond Niaura, PhD Director, Science and Training - Schroeder Institute for Tobacco Research and Policy Studies
11:20 - 11:35

Nicotine and Impact on Health – Cardiovascular and respiratory

Cardiovascular and lung safety are important considerations in the debate about the benefits versus risks of E-cigarette use. This presentation will summarize concerns and evidence on the adverse health effects of nicotine and E-cigarettes

11:35 - 11:50

Dual Use – If E-Cigarettes Are So Good, Why Are There So Few Exclusive Users?

The real public health benefit and potential for e-cigarettes can only be realized if current combustible tobacco users switch exclusively to e-cigarettes, yet current data suggests that 90% of e-cigarette users are dual users.

This session will consider the potential reasons for this.

  • Prof Jonathan Foulds Professor of Public Health Sciences and Psychiatry - Penn State Tobacco Center of Regulatory Science, Cancer Institute
11:50 - 12:05

E-Cigarette Safety & Risk Profile – Methodology and clinical relevance

An overview of research on the safety/risk profile of electronic cigarettes focusing on the interpretation of study findings and information communicated to the society, methodological problems in e-cigarette research and the need to determine and present the clinical relevance of study findings.

12:05 - 12:40

Moderated Discussion and Q&A: Risk and Harm for Individual and Population Health

  • Comparative harm of e-cigarettes and tobacco products
  • How to understand addiction as toxicity – what makes addiction a problem to society
  • What are the safety concerns that need to be addressed by regulation
  • Do e-cigarettes undermine or support smoking cessation

12:40 - 13:25

Lunch


Tobacco Control, Industry & Regulation


13:25 - 13:35

The Tobacco Industry and Tobacco Control

This session will look at tobacco industry behavior and US tobacco control.  It will consider how this shapes individual countries response to e-cigarettes and why individual context for each country is important.

  • Prof. Joanna Cohen PhD Professor of Disease Prevention and the Director of the Institute for Global Tobacco Control - Johns Hopkins Bloomberg School of Public Health
13:35 - 14:05

What Are the Key Considerations for Prudent Regulation of E-Cigarettes

Two tobacco control and health campaign advocates will discuss the regulatory considerations to maximise the potential benefits that e-cigarettes could provide current smokers and minimise the risks.  How the US regulations compare to European regulation and likely implications for tobacco control policies.

14:05 - 14:20

E-Cigarettes and Health Research

What has NIDA viewed as the key questions around e-cigarettes, and what is needed to support research on e-cigarettes? How can these needs be addressed to generate more quality research that will inform decision making for public policy.

  • Dr. Kevin Walton PhD Chief, Clinical Research Grants Branch, Division of Therapeutics and Medical Consequences - (NIDA) National Institute on Drug Abuse, NIH
14:20 - 14:35

Addressing the Challenge of ENDS Regulation

The context of conflict and effect of the crossfire
Reducing uncertainty for those in the pursuit of compliance
Building bridges in the interests of the protection of public health

  • David Graham President & Managing Partner - Reveritas Group
14:35 - 14:50

How to Regulate E-Cigarettes – Are we asking the right questions?

This presentation will consider the purposes and objectives of e-cigarette regulation, related disagreements and conflicts, and the possible components of a consensus strategy for moving forward.

  • Eric N. Lindblom JD Program Director, Tobacco Control and Food and Drug Law - O’Neill Institute for National and Global Health Law, Georgetown University Law Center
14:50 - 15:15

Open Floor Q&A and Moderated Discussion

  • What are the principles of public health that should shape the regulation of these products
  • What capacities are lacking in the regulatory/tobacco control toolkit that are needed to advance health – What changes are necessary?
  • Is an independent vaping industry important to the potential of e-cigarettes - will regulation stifle this

  • Deborah Arnott Chief Executive - Action on Smoking and Health (ASH)
  • Matthew L. Myers President - Campaign for Tobacco-Free Kids
  • Dr. Kevin Walton PhD Chief, Clinical Research Grants Branch, Division of Therapeutics and Medical Consequences - (NIDA) National Institute on Drug Abuse, NIH
  • David Graham President & Managing Partner - Reveritas Group
  • Prof. Joanna Cohen PhD Professor of Disease Prevention and the Director of the Institute for Global Tobacco Control - Johns Hopkins Bloomberg School of Public Health
  • Eric N. Lindblom JD Program Director, Tobacco Control and Food and Drug Law - O’Neill Institute for National and Global Health Law, Georgetown University Law Center
15:15 - 15:35

Afternoon Break

 


Public Health & Policy


15:35 - 15:50

Perspective from England: evidence, PHE and RCP reports

Since 1998 the UK has developed a comprehensive tobacco control strategy encompassing price rises, smoke-free legislation, treatment, mass media campaigns, pictorial health warnings, advertising ban including point of sale display ban and standardised packaging. Stemming back to Prof. Michael Russell’s influence in the 1970s and 1980s, RCP, ASH and NICE have produced reports/guidance developing the evidence base and guiding principles for harm reduction approaches. PHE commissioned stakeholder consultations and evidence reviews of electronic cigarettes in 2014 and 2015. Following the latter review, a joint statement was produced by a number of organisations. These initiatives will be discussed and the latest evidence on e-cigarette use and smoking presented.

  • Professor Ann McNeill Professor of Tobacco Addiction - UK Centre for Tobacco and Alcohol Studies (UKCTAS), Kings College London
15:50 - 16:05

E-Cigarettes and the Challenge for Clinicians

Dr Hughes will present the dilemmas that clinicians face when smokers ask a) are e-cigarettes less harmful or less addicting than cigarettes, b) can they help me quit, and c) are they better than NRT for quitting and suggest concrete evidence-based answers for these questions.     Also, he will also address a) whether clinicians should discourage smokers from using e-cigarettes to quit as a first line treatment rather than NRT or varenicline, b) how comfortable should clinicians be in recommending products that currently have not passed basic manufacturing standards, and c) how different is recommending e-cigs from recommending medical marijuana?

 

  • Prof John R Hughes Professor of Psychiatry and Psychological Science - University of Vermont
16:05 - 16:20

Reduced Nicotine Cigarettes and E-Cigarettes/ANDS

Could reducing nicotine in cigarettes have an impact on the uptake of e-cigarettes? Will this reduction speed the obsolescence of combustible tobacco products?  What would be the pros and cons of relying on e-cigarettes alone to reduce combustible tobacco product use versus regulating the nicotine content in combustible tobacco products?

  • Prof Dorothy Hatsukami Associate Director of Cancer Prevention and Control - Masonic Cancer Center, University of Minnesota
16:20 - 16:35

Are We Accurately and Usefully Presenting Information to Consumers.

The duty of an Attorney General is to act as gatekeeper and steward for consumer protection and ensure that the best scientific knowledge is accurately communicated to the public so that they can make informed decisions. AG Tom Miller historically held the tobacco industry to account for inaccurately communicating the harm and risks of their products. With the introduction of alternative nicotine delivery systems he will explore the new questions this has raised and how different perspectives on harm reduction are influencing consumers and ask what lessons can be learned.

16:35 - 17:10

Open Floor Q&A

  • What should a "balanced" debate on nicotine include and exclude
  • How do you regulate e-cigarettes to achieve the best public health outcome
  • Will regulation stifle product innovation and the opportunity that e-cigarettes could offer

17:10 - 17:15

Summary & Closing Remarks from the Chair

  • Prof Thomas J. Glynn, PhD Consulting Professor - Stanford Prevention Research Centre, Stanford University School of Medicine